Physician survey regarding updated PCV13 vaccine recommendations for adults ≥65 years.
Physician survey regarding updated PCV13 vaccine recommendations for adults ≥65 years.
复制标题
关于更新65岁以上成人PCV 13疫苗建议的医生调查。
DOI：
10.1111/jgs.17274
复制
发表时间：
2021-09
影响因子：
6.3
通讯作者：
Kempe, Allison
中科院分区：
文献类型：
--
作者：
Hurley, Laura P.;O'Leary, Sean T.;Kobayashi, Miwako;Crane, Lori A.;Cataldi, Jessica;Brtnikova, Michaela;Beaty, Brenda L.;Gorman, Carol;Lindley, Megan C.;Kempe, Allison
关键词：
2019年6月，免疫实践咨询委员会建议在≥65岁的成年人中停止常规使用肺炎球菌结合疫苗（PCV 13），而是建议根据共同临床决策（SCDM）使用PCV 13。 我们希望评估初级保健医生（1）对新SCDM PCV 13建议的知识和态度，以及（2）新建议将如何影响他们向≥65岁成人推荐PCV 13的可能性。这是通过邮件和基于互联网的调查完成的，调查于2019年10月至2020年1月进行。这项研究是在具有全国代表性的普通内科医生（GIMs）和家庭医生（FPs）样本中进行的。有效率为64%（617/968，GIM 57%，FP 71%）。只有41%的受访者知道年龄≥65岁的成人中的SCDM PCV 13建议; 76%的受访者同意（37%“强烈”，39%“有些”）他们的年龄≥65岁的患者会因SCDM推荐的PCV 13和常规推荐的肺炎球菌多糖疫苗（PPSV 23）而感到困惑; 60%的人同意（18%“强烈”，42%“有些”），他们不确定与年龄≥65岁的成人进行SCDM对话时应强调哪些要点，以接受PCV 13。超过50%的人报告说，由于新的建议，他们不太可能推荐PCV 13用于≥65岁的成年人，但42%的人报告说，他们对PCV 13的建议不会改变。需要进一步传播ACIP对≥65岁成人PCV 13的新建议。调查为什么一些医生不打算改变他们的建议是必要的。
In June 2019, the Advisory Committee on Immunization Practices recommended discontinuing the routine use of the pneumococcal conjugate vaccine (PCV13) among adults aged ≥65 years and instead recommended PCV13 be used based on shared clinical decision making (SCDM). We wanted to assess among primary care physicians (1) knowledge and attitudes regarding the new SCDM PCV13 recommendation and (2) how the new recommendation will affect their likelihood of recommending PCV13 to adults aged ≥65 years. This was done by mail and internet-based survey, which was conducted October 2019 through January 2020. The study was carried out on a nationally representative sample of general internists (GIMs) and family physicians (FPs). The response rate was 64% (617/968, GIM 57%, FP 71%). Only 41% of respondents were aware of the SCDM PCV13 recommendation in adults aged ≥65 years; 76% agreed (37% “Strongly,” 39% “Somewhat”) that their patients aged ≥65 years will get confused by having a SCDM recommendation for PCV13 and a routine recommendation for the pneumococcal polysaccharide vaccine (PPSV23); 60% agreed (18% “Strongly,” 42% “Somewhat”) that they were unsure of what points to emphasize when having a SCDM conversation with an adult aged ≥65 years about receiving PCV13. Just over 50% reported they would be less likely to recommend PCV13 for adults aged ≥65 years as a result of the new recommendation, but 42% reported that their recommendation for PCV13 would not change. Word of the new ACIP recommendation for PCV13 for adults aged ≥65 years needs to be further disseminated. Investigation into why some physicians do not plan to change their recommendations is warranted.
登录
查看更多内容
影响因子：
5.5
作者：
Pilishvili, Tamara;Bennett, Nancy M.
通讯作者：
Bennett, Nancy M.
影响因子：
2.9
作者：
Crane, Lori A.;Daley, Matthew F.;Stokley, Shannon
通讯作者：
Stokley, Shannon
影响因子：
5.5
作者：
Hurley, Laura P.;Allison, Mandy A.;Kempe, Allison
通讯作者：
Kempe, Allison
影响因子：
158.5
作者：
Bonten, M. J. M.;Huijts, S. M.;Grobbee, D. E.
通讯作者：
Grobbee, D. E.
影响因子：
5.5
作者：
Wateska, Angela R.;Nowalk, Mary Patricia;Smith, Kenneth J.
通讯作者：
Smith, Kenneth J.